top of page
Jellyfish in Aquarium_edited.jpg
Brian Kennedy.jpg

Brian Kennedy

Co-Director of the Centre for Healthy Longevity at the National University Health System

Dr. Brian Kennedy is internationally recognized for his research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of detecting, delaying, preventing, and treating human aging and associated diseases. He is a Distinguished Professor in the Department of Biochemistry and Physiology at the Yong Loo Lin School of Medicine at the National University of Singapore. He also serves as the Programme Director for the Healthy Longevity Translational Research Programme and holds the role of Co-Director at the Centre for Healthy Longevity in the National University Health System. 

Baojie Li

Professor, Shanghai Jiao Tong University

Dr. Li Baojie is a Distinguished Professor at Shanghai Jiao Tong University. From 2001 to 2009, he served as a faculty member at the Institute of Molecular and Cell Biology in Singapore. Upon returning to China, he led the 973 Project and a key project funded by the National Natural Science Foundation of China, both related to mesenchymal stem cells. Dr. Li has published over 100 SCI papers, including more than 60 as the corresponding author in journals such as Nat Genet, Nat Cell Biol, Nat Commun, Genes & Dev, EMBO J, eLife, PNAS, and Sci Transl Med. He currently serves as the Deputy Director of the Aging and Anti-Aging Science Committee of the China Geriatrics Society, Associate Editor of Frontiers in Cell and Developmental Biology, and Editorial Board Member of Cell Reg. His research interest lies in mesenchymal stem cell  


Jiankang Liu

Professor,  Xi'an Jiaotong University

Xi 'an Jiaotong University Dr. Jiankang Liu is a professor of Biochemistry, Molecular Biology and Rehabilitation Sciences, School of Health and Life Sciences, Xi 'an Jiaotong University and also serves as the Director of the Institute of Biomedicine and Health at the University of Health and Rehabilitation Sciences. His research interests include molecular and cellular mechanisms of aging, stress, and age-/stress-associated degenerative diseases with a focus on mitochondrial biology and medicine. He has published over 260 SCI papers in international academic journals, with an H-index of 77 and is the chief editor of the book Mitochondrial Medicine and Health (Science Press) and the series Mitochondrial Biomedicine: Targeting Mitochondria for the Prevention and Treatment of Major Diseases in the Human Body (10 volumes in total). For eight consecutive years (2014-2021), he has been named to Elsevier's list of the Most Cited Chinese Researchers in Biochemistry, Genetics, and Molecular Biology, and is ranked among the World's Top 1.5% Scientists from 2019 to 2021.

Yu-Xuan Lu

Researcher, Max Planck Institute for Biology of Ageing

After receiving his doctorate from Sun Yat-sen University, Dr Lu shouldered as a EMBO postdoctoral researcher at the Max Planck Institute for Biology of Ageing. His research focuses on repurposing existing drugs for interventions of ageing and age related diseases. He shoulders the first cohort of European Crucible for future research leader. Besides, Dr Lu also serves as the Co-Founder&Chair of MPCSA, A non-profit organisation for Chinese scholars associated with Max Planck Society.

Yu-Xuan Lu
Andrea Maier_edited_edited.jpg

Andrea Maier

Director, the Centre for Healthy Longevity, National University Health System

Professor Maier serves at the National University of Singapore as Co-Director of the Centre for Healthy Longevity as well as the President of the Australian and New Zealand Society for Sarcopenia and Frailty Research.  Her research focuses on unraveling the mechanisms of ageing and age-related diseases. During the last 10 years she has conducted multiple international observational studies and intervention trials and has published more than 300 peer-reviewed articles, achieving an H index of 54. 

Joan Mannick

Co-Founder and CEO, Tornado Therapeutics

Joan Mannick is the Chief Executive Officer and Co-Founder of Tornado Therapeutics which is developing next generation mTOR inhibitors to treat aging-related diseases. Prior to joining Tornado, She was Head of Research and Development at Life Biosciences and Chief Medical Officer of resTORbio.

Dr. Mannick was faculty member at Harvard Medical School and University of Massachusetts Medical School. Dr. Mannick received her A.B. from Harvard College and her M.D. from Harvard Medical School. She completed her residency in Internal Medicine and an Infectious Disease fellowship at Harvard Medical School.

Joan Mannick_edited.jpg

Elizabeth Parrish

CEO, BioViva Science

Elizabeth (Liz) Parrish MBA, is the Founder and CEO of BioViva Sciences USA Inc. She is a humanitarian, entrepreneur, author, and innovator. She is a proponent of the Best Choice Medicine plan (BCM), a more efficient and streamlined regulatory model around the use of genetic therapies. She is actively involved in international educational media outreach and is a founding member of several 501(c)(3) nonprofits in the space. Her company BioViva is committed to extending healthy lifespans using gene therapy. BioViva works on combinatorial gene therapies with its proprietary CMV gene therapy delivery platform. 

Ruibao Ren

Director, International Center for Aging and Cancer, Hainan Medical University Director, Shanghai Institute of Hematology

Professor Ren Director of Shanghai Institute of Hematology, National Distinguished Expert, Professor "Wang Kuancheng" of Shanghai Jiao Tong University, Researcher of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Researcher of Hainan Medical College, Doctoral supervisor, American journal of blood and oncology "JHO" and the journal of Aging and Cancer "deputy editor. He was a postdoctoral fellow in the laboratory of David Baltimore, a Nobel Prize winner at Rockefeller University. He is committed to the molecular detection, mechanism and targeted therapy research of Blood system aging and leukemia. He has published more than 90 papers in important academic journals such as Cell, Nature, Science and Blood, and three scientific and technological achievements transformation.

Ruibao Ren_edited.jpg
Björn Schumacher1_edited.jpg

Björn Schumacher

Director, Institute for Genome Stability in Ageing and Disease, Medical Faculty, University of Cologne

Prof. Schumacher is the President of the German Society for DNA Repair (DGDR), co-Director of the Minerva Center of the Biological Mechanisms of Healthy Ageing at Bar-Ilan University (IL). He was awarded with the Eva Luise Köhler Research Prize, the Innovation Prize of the State of North Rhine-Westphalia, the European Research Council (ERC) starting grant, coordinated the FP7 Marie Curie initial training network on chronic DNA damage in ageing (CodeAge) and serves on several editorial boards. His research interest focuses on the molecular mechanisms through which DNA damage contributes to cancer development and ageing-associated diseases.

Andrei Seluanov

Professor, University of Rochester

Prof. Andrei Seluanov is a Professor of Biology and Medicine at the University of Rochester. His research is focused on understanding the mechanisms of longevity and genome stability and on the studies of exceptionally long-lived and cancer- resistant mammals. Prof. Seluanov’s work has been published in journals including Nature, Science, and Cell. He received awards from the Ellison Medical Foundation, Life Extension Foundation, the National Institutes of Health and was awarded the Cozzarelli Prize from PNAS for outstanding scientific excellence and originality, Prince Hitachi Prize in Comparative Oncology (Japan), and Davey Prize from the University of Rochester Wilmot Cancer Center. 

Andrei Seluanov_edited.jpg
bottom of page